Of the two ipilimumab dosing schedules utilized with nivolumab on CheckMate 8HW, do you have a preference in your own practice?

As ipilimumab often drives the increased toxicity of dual checkpoint inhibitors in comparison to monotherapy, multiple dosing regimens have been used across tumor types. Patients tend to do better with either short courses of ipilimumab (such as the Q3 week dosing for 4 cycles) or longer periods bet...

Before the CheckMate 8HW reported data compared nivolumab/ipilimumab vs nivolumab, the strongest evidence we have is from the indirect comparison from the two later-line arms, including the phase II CheckMate142 study (Lenz et al, PMID: 34637336) which showed response rates for nivolumab and nivolum...